Drug intelligence / Profile preview

mRNA-0523-L001

Development stage: Phase 1
Lead developer: Shanghai Jiao Tong University School of Medicine
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Injection

Overview

mRNA-0523-L001 is an individualized mRNA neoantigen vaccine designed to treat advanced endocrine tumors. The vaccine is personalized for each patient, encoding tumor-specific neoantigens identified from the patient's own tumor. It is delivered using lipid nanoparticles via injection. The vaccine aims to stimulate the patient's immune system to recognize and attack cancer cells expressing these specific neoantigens.

Other names: Individualized mRNA neoantigen vaccine

Targets

γδ TCR (T-cell receptor)

Beyond the preview

Go deeper on mRNA-0523-L001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mRNA-0523-L001.

Explore the full profile